Crystal Research Associates has issued a 9-page Quarterly Update on clinical-stage biotechnology company, Emmaus Life Sciences, Inc. (EMMA-OTCQX).
/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
September 8, 2023 at 9:45 AM
Crystal Research Associates has issued a 9-page Quarterly Update on clinical-stage biotechnology company, Emmaus Life Sciences, Inc. (EMMA-OTCQX).
Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, sickle cell disease, L-glutamine, endari, diverticulosis
January 24, 2023 at 3:17 PM
An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, emmaus life sciences, sickle cell disease, L-glutamine, endari, diverticulosis
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS